Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Vir Biotechnology, Inc. (VIR : NSDQ)
 
 • Company Description   
Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.

Number of Employees: 444

 
 • Price / Volume Information   
Yesterday's Closing Price: $24.36 Daily Weekly Monthly
20 Day Moving Average: 1,029,971 shares
Shares Outstanding: 132.38 (millions)
Market Capitalization: $3,224.68 (millions)
Beta: -0.55
52 Week High: $58.00
52 Week Low: $18.21
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 11.18% 25.21%
12 Week -13.68% -5.11%
Year To Date -41.82% -27.25%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
499 ILLINOIS STREET SUITE 500
-
SAN FRANCISCO,CA 94158
USA
ph: 415-906-4324
fax: -
ir@vir.bio http://www.vir.bio
 
 • General Corporate Information   
Officers
George Scangos - President; Chief Executive Officer and Director
Vicki Sato - Chairman
Howard Horn - Chief Financial Officer and Secretary
Jeffrey S. Hatfield - Director
Robert More - Director

Peer Information
Vir Biotechnology, Inc. (CORR.)
Vir Biotechnology, Inc. (RSPI)
Vir Biotechnology, Inc. (CGXP)
Vir Biotechnology, Inc. (BGEN)
Vir Biotechnology, Inc. (GTBP)
Vir Biotechnology, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92764N102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 132.38
Most Recent Split Date: (:1)
Beta: -0.55
Market Capitalization: $3,224.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.16 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 11.02% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 11.28
Trailing 12 Months: 2.69
PEG Ratio: 1.02
Price Ratios
Price/Book: 1.61
Price/Cash Flow: 5.97
Price / Sales: 1.39
EPS Growth
vs. Year Ago Period: 391.67%
vs. Previous Quarter: -1.79%
Sales Growth
vs. Year Ago Period: 62,271.41%
vs. Previous Quarter: 51.64%
ROE
03/31/22 - 96.39
12/31/21 - 57.20
09/30/21 - -13.73
ROA
03/31/22 - 68.43
12/31/21 - 39.46
09/30/21 - -9.47
Current Ratio
03/31/22 - 3.66
12/31/21 - 4.58
09/30/21 - 4.56
Quick Ratio
03/31/22 - -
12/31/21 - 4.58
09/30/21 - 4.56
Operating Margin
03/31/22 - 52.29
12/31/21 - 48.26
09/30/21 - -35.98
Net Margin
03/31/22 - 52.29
12/31/21 - 48.26
09/30/21 - -35.98
Pre-Tax Margin
03/31/22 - 70.53
12/31/21 - 50.19
09/30/21 - -35.78
Book Value
03/31/22 - 15.12
12/31/21 - 10.94
09/30/21 - 6.71
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©